

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement



杭州啓明醫療器械股份有限公司

Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

**FURTHER ANNOUNCEMENT
IN RELATION TO THE PATENT INFRINGEMENT LAWSUIT**

Reference is made to the announcement of Venus Medtech (Hangzhou) Inc. (the “**Company**”) dated January 20, 2026 in relation to a patent infringement lawsuit.

The Company wishes to provide further information to the shareholders and potential investors of the Company on the Lawsuit (as defined below).

On June 9, 2025, the United States Court of Appeals for the Federal Circuit issued a decision affirming the patentability of the certain claims of U.S. Patent No. 10,702,385 (Implant for Heart Valve) (the “**US '385 Patent**”) owned by Cardiovalve Ltd., which had been challenged by Edwards Lifesciences Corp. and Edwards Lifesciences LLC (collectively, “**Edwards**”) in an *inter partes* review proceeding in June 2021.

On January 14, 2026, Cardiovalve Ltd. and MTH IP, L.P. filed a patent infringement lawsuit against Edwards in relation to US '385 Patent in the United States District Court for the District of Delaware (the “**Lawsuit**”), alleging that Edwards’ core product, PASCAL Precision Transcatheter Valve Repair System, infringes upon US '385 Patent owned by Cardiovalve Ltd.

As the Lawsuit is still at a preliminary stage, further details (including the possible claim amount) remain subject to the outcome of the Lawsuit. The Company will make further announcements regarding any substantive progress of the Lawsuit in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Venus Medtech (Hangzhou) Inc.
Mr. Lim Hou-Sen (Lin Haosheng)
Executive Director

Hangzhou, January 22, 2026

As at the date of this announcement, the executive Directors are Mr. Lim Hou-Sen (Lin Haosheng), Mr. Liqiao Ma and Ms. Meirong Liu; the non-executive Directors are Mr. Ao Zhang and Mr. Wei Wang; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Chi Wai Suen and Mr. John Junhua Gu.